Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of the A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

NCT02990416 is registered in ClinicalTrials.gov with Virogen Biotechnology Inc. as lead sponsor.

NCT NCT02990416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02990416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of the A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
Lead sponsor
Virogen Biotechnology Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2017
Completion date
June 30, 2018
Enrollment
63 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv melanoma